BY MARKETWIRE
-
Novo Nordisk’s Wegovy approved for cardiovascular disease treatment in China
About 4 million fatalities in China annually are credited to heart disease, states Novo Nordisk.
-
Pfizer delivers lackluster revenue forecast
The pharmaceutical gigantic anticipates to attain profits of USD 59.5-62.5 billion in 2026.
-
Eli Lilly submits application for new weight-loss tablet
In November, Eli Lilly protected an FDA top priority testimonial coupon, making it possible for an increased testimonial of its application.
-
A booming stock market listing: Medline rises more than 25%
This likewise provides the firm, which is generally possessed by the exclusive equity funds Blackstone, Carlyle Team, and Hellman & Friedman, a market price of greater than US…
-
Novo Nordisk aims to regain the weight loss market
Novo Nordisk have to end up being a lot more consumer-oriented and assume even more like Amazon by supplying consumers the very same rate and versatility, according to chief execut…
-
DNB Carnegie cuts its estimates for Novo Nordisk’s future earnings
This is based upon weak energy heading right into 2026 and Novo Nordisk’s most recent rate arrangement with United States Head of state Donald Trump.
-
Pfizer delivers lackluster revenue forecast
The pharmaceutical giant expects to achieve revenue of USD 59.5-62.5 billion in 2026.
-
Genmab partner gets FDA approval for expanded use of lung cancer drug
The medicine Rybrevant currently has an extensive FDA authorization for usage in lung cancer cells clients.
-
Employees say strategy change eroded Novo Nordisk’s market lead
In 2017, Novo Nordisk altered its research study technique and changed emphasis far from its core locations– a choice that present and previous staff members state exists at …
-
Roche and Novartis close to price agreement with Trump
The contract is anticipated to be comparable to those participated in by both Novo Nordisk and Eli Lilly with Head Of State Donald Trump and his management in November.
